![Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology](https://www.thelancet.com/cms/asset/28f62488-d818-4e72-ba24-1636b3b8d894/gr1.jpg)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
![Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer | Research To Practice Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_page_image/slideshow_page/33074/Slide1.jpg)
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer | Research To Practice
![PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis](https://i1.rgstatic.net/publication/5461472_Healing_by_primary_closure_versus_open_healing_after_surgery_for_pilonidal_sinus_Systemic_review_and_meta-analysis/links/0deec514b36081b9fe000000/largepreview.png)
PDF) Healing by primary closure versus open healing after surgery for pilonidal sinus: Systemic review and meta-analysis
![Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2092216225/2076440337/gr1.gif)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet
![Cancers | Free Full-Text | Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer Cancers | Free Full-Text | Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer](https://www.mdpi.com/cancers/cancers-14-00253/article_deploy/html/images/cancers-14-00253-g001.png)
Cancers | Free Full-Text | Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer
![Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time | British Journal of Cancer Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.314/MediaObjects/41416_2016_Article_BFbjc2015314_Fig1_HTML.jpg)
Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time | British Journal of Cancer
![Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials - The Lancet Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/2003018872/2011627633/gr1.jpg)